Abstract:Generation of chimeric antigen receptor macrophages (CAR-M) from human pluripotent stem cells (hPSCs) holds new prospects for tumor immunotherapy, but currently is challenged by low differentiation efficiency and limited function. Here, we develop a highly efficient monolayer system that increases the production of CAR-M by more than 100 times, enabling a single hPSC to produce up to 6000 CAR-M within 3 weeks. By optimizing CAR structure, we generate hPSC-CAR-M with stable CAR expression and potent tumoricidal activity in vitro. To overcome the lost tumoricidal activity of hPSC-CAR-M in vivo, we use interferon-γ and toll-like receptor 4 agonist to activate innate immunity in vivo that improves the antitumor potential of hPSC-CAR-M. Moreover, we demonstrate that activating a collaborative innate-adaptive immune response can further enhance the anti-tumor effect of hPSC-CAR-M in vivo. Collectively, our study provides feasible methodologies that significantly improve the production and antitumor activity of hPSC-CAR-M to support the translation of hPSC-based immunotherapies to clinical applications. Generation of chimeric antigen receptor macrophages (CAR-M) from human pluripotent stem cells (hPSCs) holds new prospects for tumor immunotherapy, but currently is challenged by low differentiation efficiency and limited function. Here, we develop a highly efficient monolayer system that increases the production of CAR-M by more than 100 times, enabling a single hPSC to produce up to 6000 CAR-M within 3 weeks. By optimizing CAR structure, we generate hPSC-CAR-M with stable CAR expression and potent tumoricidal activity in vitro. To overcome the lost tumoricidal activity of hPSC-CAR-M in vivo, we use interferon-γ and toll-like receptor 4 agonist to activate innate immunity in vivo that improves the antitumor potential of hPSC-CAR-M. Moreover, we demonstrate that activating a collaborative innate-adaptive immune response can further enhance the anti-tumor effect of hPSC-CAR-M in vivo. Collectively, our study provides feasible methodologies that significantly improve the production and antitumor activity of hPSC-CAR-M to support the translation of hPSC-based immunotherapies to clinical applications.

Human Pluripotent Stem Cell-Derived Eosinophils Reveal Potent Cytotoxicity Against Solid Tumors.

Cisplatin Plus Anti-Pd-1 Antibody Enhanced Treatment Efficacy in Advanced Esophageal Squamous Cell Carcinoma.

Prognostic Impact of Peripheral Eosinophil Counts in Patients with Diffuse Large B-cell Lymphoma Receiving Chimeric Antigen Receptor T-cell Therapy.

Chimeric Antigen Receptor-Modified T Cells Redirected to EphA2 for the Immunotherapy of Non-Small Cell Lung Cancer

Vaccination with human pluripotent stem cells generates a broad spectrum of immunological and clinical responses against colon cancer.

Potential Roles of Eosinophils in Cancer Therapy: Epidemiological Studies, Experimental Models, and Clinical Pathology.

Antitumor effects of CD40 ligand-expressing endothelial progenitor cells derived from human induced pluripotent stem cells in a metastatic breast cancer model.

3176 – EFFECTIVE PRODUCTION OF HIGHLY FUNCTIONAL CAR-MACROPHAGES FROM HUMAN PLURIPOTENT STEM CELLS FOR CANCER IMMUNOTHERAPY

Eosinophil‐activating Semiconducting Polymer Nanoparticles for Cancer Photo‐immunotherapy

Expression Levels of a Gene Signature in Hipsc Associated with Lung Adenocarcinoma Stem Cells and Its Capability in Eliciting Specific Antitumor Immune‐response in a Humanized Mice Model

'Off the shelf' immunotherapies: Generation and application of pluripotent stem cell‐derived immune cells

Abstract 3155: "super NK Cells" - Natural Killer Cells Derived from Engineered Hipsc with Enhanced NK Receptor Expression Demonstrate Better Anti-Tumor Effects for Solid Tumors

Concise Review: Human Pluripotent Stem Cells to Produce Cell-Based Cancer Immunotherapy

Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer

Adoptive Immunotherapy: A Human Pluripotent Stem Cell Perspective

Adoptive Cell Therapy from the Dish: Potentiating Induced Pluripotent Stem Cells

Efficacy of the induced pluripotent stem cell derived and engineered CD276-targeted CAR-NK cells against human esophageal squamous cell carcinoma

A new dawn for eosinophils in the tumour microenvironment

Chimeric Antigen Receptor–modified T Cells Repressed Solid Tumors and Their Relapse in an Established Patient-derived Colon Carcinoma Xenograft Model

Neoantigen Specific T Cells Derived From T Cell-Derived Induced Pluripotent Stem Cells For The Treatment Of Hepatocellular Carcinoma: Potential And Challenges

Targeted Hsp70 Expression Combined with Cik-Activated Immune Reconstruction Synergistically Exerts Antitumor Efficacy in Patient-Derived Hepatocellular Carcinoma Xenograft Mouse Models